Last reviewed · How we verify

Hib conjugate vaccine (ActHIB)

GlaxoSmithKline · Phase 3 active Biologic

Hib conjugate vaccine (ActHIB) is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children. Also known as: ActHIB.

ActHIB is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.

ActHIB is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier. Used for Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children.

At a glance

Generic nameHib conjugate vaccine (ActHIB)
Also known asActHIB
SponsorGlaxoSmithKline
Drug classConjugate vaccine
TargetHaemophilus influenzae type b polysaccharide capsule
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains the polysaccharide capsule of Haemophilus influenzae type b conjugated to a protein carrier (typically tetanus toxoid or meningococcal outer membrane protein), which enhances immunogenicity and T-cell dependent immune response. This conjugation allows the vaccine to elicit both antibody production and immunological memory, providing protection against invasive Hib disease including meningitis, bacteremia, and epiglottitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hib conjugate vaccine (ActHIB)

What is Hib conjugate vaccine (ActHIB)?

Hib conjugate vaccine (ActHIB) is a Conjugate vaccine drug developed by GlaxoSmithKline, indicated for Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children.

How does Hib conjugate vaccine (ActHIB) work?

ActHIB is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.

What is Hib conjugate vaccine (ActHIB) used for?

Hib conjugate vaccine (ActHIB) is indicated for Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children.

Who makes Hib conjugate vaccine (ActHIB)?

Hib conjugate vaccine (ActHIB) is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Hib conjugate vaccine (ActHIB) also known as anything else?

Hib conjugate vaccine (ActHIB) is also known as ActHIB.

What drug class is Hib conjugate vaccine (ActHIB) in?

Hib conjugate vaccine (ActHIB) belongs to the Conjugate vaccine class. See all Conjugate vaccine drugs at /class/conjugate-vaccine.

What development phase is Hib conjugate vaccine (ActHIB) in?

Hib conjugate vaccine (ActHIB) is in Phase 3.

What are the side effects of Hib conjugate vaccine (ActHIB)?

Common side effects of Hib conjugate vaccine (ActHIB) include Local injection site reactions (erythema, swelling, induration), Fever, Irritability, Drowsiness.

What does Hib conjugate vaccine (ActHIB) target?

Hib conjugate vaccine (ActHIB) targets Haemophilus influenzae type b polysaccharide capsule and is a Conjugate vaccine.

Related